My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Deciphera Pharmaceuticals (DCPH)
DCPH nasdaq
United States
Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Stock Analysis & Ratings

Deciphera Pharmaceuticals Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Deciphera Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


DCPH Stock Stats

Previous Close$8.35
Bid0 x 0
Ask0 x 0
Today’s Range$7.93 - $8.38
52-Week Range$8.09 - $62.97
Average Volume1.15M
Market Cap$471.94M
P/E Ratio-1.7
Earnings DateMar 16, 2022

Company Description

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Steven L. Hoerter
200 Smith Street, Waltham, MA, 02451, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Deciphera Pharmaceuticals’s price range in the past 12 months?
Deciphera Pharmaceuticals lowest stock price was $8.09 and its highest was $62.97 in the past 12 months.
    What is Deciphera Pharmaceuticals’s market cap?
    Deciphera Pharmaceuticals’s market cap is $471.94M.
      What is Deciphera Pharmaceuticals’s price target?
      The average price target for Deciphera Pharmaceuticals is $21.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $64.00 ,the lowest forecast is $5.00. The average price target represents 166.42% Increase from the current price of $8.07.
        What do analysts say about Deciphera Pharmaceuticals?
        Deciphera Pharmaceuticals’s analyst rating consensus is a ‘Hold. This is based on the ratings of 10 Wall Streets Analysts.
          When is Deciphera Pharmaceuticals’s upcoming earnings report date?
          Deciphera Pharmaceuticals’s upcoming earnings report date is Mar 16, 2022 which is in 108 days.
            How were Deciphera Pharmaceuticals’s earnings last quarter?
            Deciphera Pharmaceuticals released its earnings results on Nov 02, 2021. The company reported -$1.37 earnings per share for the quarter, missing the consensus estimate of -$1.244 by -$0.126.
              Is Deciphera Pharmaceuticals overvalued?
              According to Wall Street analysts Deciphera Pharmaceuticals’s price is currently Undervalued.
                Does Deciphera Pharmaceuticals pay dividends?
                Deciphera Pharmaceuticals does not currently pay dividends.
                What is Deciphera Pharmaceuticals’s EPS estimate?
                Deciphera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Deciphera Pharmaceuticals have?
                Deciphera Pharmaceuticals has 58,480,000 shares outstanding.
                  What happened to Deciphera Pharmaceuticals’s price movement after its last earnings report?
                  Deciphera Pharmaceuticals reported an EPS of -$1.37 in its last earnings report, missing expectations of -$1.244. Following the earnings report the stock price went up 8.219%.
                    Which hedge fund is a major shareholder of Deciphera Pharmaceuticals?
                    Among the largest hedge funds holding Deciphera Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Deciphera Pharmaceuticals’s shares valued at 28M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis